Hemispherx Fails to Win U.S. Approval for Chronic Fatigue

Hemispherx Biopharma Inc., the maker of an injectable medicine for genital warts, failed for the second time to win U.S. approval for a drug to treat chronic fatigue syndrome.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.